| Bioactivity | Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy[1][2][3][4]. | ||||||||||||
| Invitro | Zonisamide (10, 50, 100, 200 µM; 24 h) increases viability of SH-SY5Y cells via an anti-apoptotic effect[1].Zonisamide (100 µM; 24 h) shows neuroprotective effects in PD-cellular models. (PD: parkinson’s disease)[1].Zonisamide (100 µM; 24 h) reduces levels of proapoptotic molecules, and upregulates levels of MnSOD (MnSOD over-expression attenuates MPTP toxicity and protects cells from apoptosis)[1].Zonisamide (0.1, 0.3, 1 μM; 24 h) inhibits cardiac hypertrophy and fibrosis in vitro[3].Zonisamide markedly increases the expression of Hrd1 in Ang II-treated NRCMs[3]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | Zonisamide | ||||||||||||
| CAS | 68291-97-4 | ||||||||||||
| Formula | C8H8N2O3S | ||||||||||||
| Molar Mass | 212.23 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
Zonisamide
CAS: 68291-97-4 F: C8H8N2O3S W: 212.23
Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V,
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.